AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

ivonescimabPositive

AI Analysis

Summary

AstraZeneca invests $2 billion in Summit Therapeutics to support ivonescimab development, while uniQure's Huntington's disease gene therapy disappoints in four-year data readout. Kyverna advances CAR-T therapy in autoimmune disease.

Outcome Details

AstraZeneca invests $2 billion in Summit Therapeutics; uniQure four-year Huntington's disease gene therapy data disappointing

Importance:7/10

Sentiment:

0.30

investmentgene_therapyCAR-Tlate-stage developmentnegative data

Related Companies

$AZN $QURE

Read the original article

Published by BioSpace on September 30, 2026 10:07 AM

Read Original